
Sviluppo
Business·7/23/2026Riepilogo dell'IA
Eli Lilly Delays Next-Generation Obesity Drug Approval Filing to Early 2027 After Successful Trials
Eli Lilly announced it will file for approval of its next-generation obesity drug, retatrutide, in Q1 2027, later than previously stated. This follows successful late-stage trials showing significant weight loss in adults with obesity, Type 2 diabetes, and cardiovascular disease.
C
CNBC World2 min read
